» Articles » PMID: 16597201

Treatment Options for Visceral Leishmaniasis

Overview
Date 2006 Apr 7
PMID 16597201
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

This review summarizes the current developments in therapy for visceral leishmaniasis. With the recent introduction of new drugs, the main limits in reducing deaths from visceral leishmaniasis are difficulty in diagnosis in the field and health inequality--patients lack of access to treatment. No new drugs are currently in the early stages of development. There are good reasons for the use of combination therapy; to prevent further development of resistance against the limited therapeutic options available.

Citing Articles

Redox-Based Strategies against Infections by Eukaryotic Pathogens.

Vallieres C, Golinelli-Cohen M, Guittet O, Lepoivre M, Huang M, Vernis L Genes (Basel). 2023; 14(4).

PMID: 37107536 PMC: 10138290. DOI: 10.3390/genes14040778.


Amphotericin B-PEG Conjugates of ZnO Nanoparticles: Enhancement Antifungal Activity with Minimal Toxicity.

Alshahrani S, Khafagy E, Riadi Y, Al Saqr A, Alfadhel M, Hegazy W Pharmaceutics. 2022; 14(8).

PMID: 36015271 PMC: 9415822. DOI: 10.3390/pharmaceutics14081646.


Hemoglobin Endocytosis and Intracellular Trafficking: A Novel Way of Heme Acquisition by .

Ansari I, Basak R, Mukhopadhyay A Pathogens. 2022; 11(5).

PMID: 35631106 PMC: 9143042. DOI: 10.3390/pathogens11050585.


A case report and literature review: diagnosis and treatment of human immunodeficiency virus coinfected with visceral leishmania by metagenomic next-generation sequencing in China.

Tang C, He S, Wang N, Chen L Ann Transl Med. 2022; 10(8):497.

PMID: 35571385 PMC: 9096369. DOI: 10.21037/atm-22-1351.


Identification of Leucinostatins from sp. as Antiparasitic Agents against .

Bernatchez J, Kil Y, Barbosa da Silva E, Thomas D, McCall L, Wendt K ACS Omega. 2022; 7(9):7675-7682.

PMID: 35284725 PMC: 8908367. DOI: 10.1021/acsomega.1c06347.